619 related articles for article (PubMed ID: 22711607)
41. Identification of aberrant cell cycle regulation in Epstein-Barr virus-associated nasopharyngeal carcinoma by cDNA microarray and gene set enrichment analysis.
Zhang W; Zeng Z; Zhou Y; Xiong W; Fan S; Xiao L; Huang D; Li Z; Li D; Wu M; Li X; Shen S; Wang R; Cao L; Tang K; Li G
Acta Biochim Biophys Sin (Shanghai); 2009 May; 41(5):414-28. PubMed ID: 19430707
[TBL] [Abstract][Full Text] [Related]
42. MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.
de Leeuw R; McNair C; Schiewer MJ; Neupane NP; Brand LJ; Augello MA; Li Z; Cheng LC; Yoshida A; Courtney SM; Hazard ES; Hardiman G; Hussain MH; Diehl JA; Drake JM; Kelly WK; Knudsen KE
Clin Cancer Res; 2018 Sep; 24(17):4201-4214. PubMed ID: 29739788
[No Abstract] [Full Text] [Related]
43. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
44. Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Ouyang Z; Wang S; Zeng M; Li Z; Zhang Q; Wang W; Liu T
Cell Commun Signal; 2019 Feb; 17(1):17. PubMed ID: 30808351
[TBL] [Abstract][Full Text] [Related]
45. The atr protein kinase controls UV-dependent upregulation of p16INK4A through inhibition of Skp2-related polyubiquitination/degradation.
Al-Khalaf HH; Hendrayani SF; Aboussekhra A
Mol Cancer Res; 2011 Mar; 9(3):311-9. PubMed ID: 21270107
[TBL] [Abstract][Full Text] [Related]
46. CDK redundancy guarantees cell cycle progression in Rb-negative tumor cells independently of their p16 status.
Santamariña M; Hernández G; Zalvide J
Cell Cycle; 2008 Jul; 7(13):1962-72. PubMed ID: 18604173
[TBL] [Abstract][Full Text] [Related]
47. Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.
Olmez I; Brenneman B; Xiao A; Serbulea V; Benamar M; Zhang Y; Manigat L; Abbas T; Lee J; Nakano I; Godlewski J; Bronisz A; Abounader R; Leitinger N; Purow B
Clin Cancer Res; 2017 Nov; 23(22):6958-6968. PubMed ID: 28814434
[No Abstract] [Full Text] [Related]
48. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Gelbert LM; Cai S; Lin X; Sanchez-Martinez C; Del Prado M; Lallena MJ; Torres R; Ajamie RT; Wishart GN; Flack RS; Neubauer BL; Young J; Chan EM; Iversen P; Cronier D; Kreklau E; de Dios A
Invest New Drugs; 2014 Oct; 32(5):825-37. PubMed ID: 24919854
[TBL] [Abstract][Full Text] [Related]
49. The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome.
Chien WW; Catallo R; Chebel A; Baranger L; Thomas X; Béné MC; Gerland LM; Schmidt A; Beldjord K; Klein N; Escoffre-Barbe M; Leguay T; Huguet F; Larosa F; Hayette S; Plesa A; Ifrah N; Dombret H; Salles G; Chassevent A; Ffrench M
Leuk Res; 2015 Apr; 39(4):453-61. PubMed ID: 25675863
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells.
Liu S; Tang Y; Yuan X; Yuan D; Liu J; Li B; Li Y
Invest New Drugs; 2018 Dec; 36(6):961-969. PubMed ID: 29508248
[TBL] [Abstract][Full Text] [Related]
51. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments.
Witkiewicz AK; Knudsen KE; Dicker AP; Knudsen ES
Cell Cycle; 2011 Aug; 10(15):2497-503. PubMed ID: 21775818
[TBL] [Abstract][Full Text] [Related]
52. Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro.
Schrage YM; Lam S; Jochemsen AG; Cleton-Jansen AM; Taminiau AH; Hogendoorn PC; Bovée JV
J Cell Mol Med; 2009 Sep; 13(9A):2843-52. PubMed ID: 18624751
[TBL] [Abstract][Full Text] [Related]
53. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
54. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas.
Burns KL; Ueki K; Jhung SL; Koh J; Louis DN
J Neuropathol Exp Neurol; 1998 Feb; 57(2):122-30. PubMed ID: 9600204
[TBL] [Abstract][Full Text] [Related]
55. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.
Tang LH; Contractor T; Clausen R; Klimstra DS; Du YC; Allen PJ; Brennan MF; Levine AJ; Harris CR
Clin Cancer Res; 2012 Sep; 18(17):4612-20. PubMed ID: 22761470
[TBL] [Abstract][Full Text] [Related]
56. A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target.
Franceschini N; Gaeta R; Krimpenfort P; Briaire-de Bruijn I; Kruisselbrink AB; Szuhai K; Palubeckaitė I; Cleton-Jansen AM; Bovée JVMG
Lab Invest; 2022 Apr; 102(4):391-400. PubMed ID: 34921235
[TBL] [Abstract][Full Text] [Related]
57. Controversial relationship between the expression of the RB pathway components and RB protein phosphorylation in human breast cancer.
Montanaro L; Vici M; Donati G; Ceccarelli C; Santini D; Treré D; Derenzini M
Histol Histopathol; 2007 Jul; 22(7):769-75. PubMed ID: 17455150
[TBL] [Abstract][Full Text] [Related]
58. Growth inhibitory effect on glioma cells of adenovirus-mediated p16/INK4a gene transfer in vitro and in vivo.
Lee SH; Kim MS; Kwon HC; Park IC; Park MJ; Lee CT; Kim YW; Kim CM; Hong SI
Int J Mol Med; 2000 Nov; 6(5):559-63. PubMed ID: 11029524
[TBL] [Abstract][Full Text] [Related]
59. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
60. CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms.
Skowron MA; Vermeulen M; Winkelhausen A; Becker TK; Bremmer F; Petzsch P; Schönberger S; Calaminus G; Köhrer K; Albers P; Nettersheim D
Br J Cancer; 2020 Aug; 123(3):378-391. PubMed ID: 32418994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
